Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT2 | Q96PD7 | 7/20 | 0.33 |
| ▸ | MET | P08581 | 4/20 | 0.33 |
| ▸ | AXL | P30530 | 4/20 | 0.33 |
| ▸ | TYRO3 | Q06418 | 4/20 | 0.33 |
| ▸ | MERTK | Q12866 | 4/20 | 0.33 |
| ▸ | CTSA | P10619 | 4/20 | 0.33 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.31 |
| ▸ | FABP7 | O15540 | 1/20 | 0.31 |
| ▸ | FABP3 | P05413 | 1/20 | 0.31 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.31 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.31 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13672548 | 1.00 | DGAT2 (0.33) | DGAT2METAXLTYRO3MERTK | |
| SCHEMBL4480988 | 0.89 | PDE10A (0.34) | DGAT2METAXLTYRO3MERTK | |
| SCHEMBL13672547 | 0.89 | PDE10A (0.34) | DGAT2METAXLTYRO3MERTK | |
| SCHEMBL4475774 | 0.87 | MAPK14 (0.42) | DGAT2MAPK14 | |
| SCHEMBL4479724 | 0.87 | FABP3 (0.37) | DGAT2METAXLTYRO3MERTK | |
| SCHEMBL4480138 | 0.87 | FABP3 (0.37) | DGAT2METAXLTYRO3MERTK | |
| SCHEMBL13672572 | 0.86 | DGAT1 (0.34) | DGAT2METAXLTYRO3MERTK | |
| SCHEMBL4755290 | 0.84 | FABP3 (0.36) | DGAT2CTSAFABP7FABP3FABP5 | |
| SCHEMBL4481511 | 0.79 | PDE10A (0.33) | DGAT2METAXLTYRO3MERTK | |
| SCHEMBL4481505 | 0.79 | PDE10A (0.33) | DGAT2METAXLTYRO3MERTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7608603-B2 | Substituted pyrazolo[3,4-D]pyrimidines as p38 MAP kinase inhibitors | ROCHE PALO ALTO LLC (US) | 2009-10-27 | — | — | US | claimed |
| US-7608603-B2 | Substituted pyrazolo[3,4-D]pyrimidines as p38 MAP kinase inhibitors | ROCHE PALO ALTO LLC (US) | 2009-10-27 | — | — | US | disclosed |
| US-20070049597-A1 | p38 MAP kinase inhibitors and methods for using the same | ROCHE PALO ALTO LLC | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049597-A1 | p38 MAP kinase inhibitors and methods for using the same | MAPK1, MAPK9, MAPK3 | DGAT2 4297/4885MET 1608/4885AXL 1795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.